Display options
Cite
Langan RC, Mullinax JE, Ray S, et al. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. J Cancer. 2012;3:231-40doi: 10.7150/jca.4542.
Langan, R. C., Mullinax, J. E., Ray, S., Raiji, M. T., Schaub, N., Xin, H. W., Koizumi, T., Steinberg, S. M., Anderson, A., Wiegand, G., Butcher, D., Anver, M., Bilchik, A. J., Stojadinovic, A., Rudloff, U., & Avital, I. (2012). A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. Journal of Cancer, 3231-40. https://doi.org/10.7150/jca.4542
Langan, Russell C, et al. "A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers." Journal of Cancer vol. 3 (2012): 231-40. doi: https://doi.org/10.7150/jca.4542
Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U, Avital I. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. J Cancer. 2012;3:231-40. doi: 10.7150/jca.4542. Epub 2012 Jun 01. PMID: 22670157; PMCID: PMC3366478.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2012;3:231-40. doi: 10.7150/jca.4542. Epub 2012 Jun 01.

A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers.

Journal of Cancer

Russell C Langan, John E Mullinax, Satyajit Ray, Manish T Raiji, Nicholas Schaub, Hong-Wu Xin, Tomotake Koizumi, Seth M Steinberg, Andrew Anderson, Gordon Wiegand, Donna Butcher, Miriam Anver, Anton J Bilchik, Alexander Stojadinovic, Udo Rudloff, Itzhak Avital

Affiliations

  1. 1. National Cancer Institute, National Institutes of Health, Bethesda, MD.

PMID: 22670157 PMCID: PMC3366478 DOI: 10.7150/jca.4542

Abstract

INTRODUCTION: Over 50% of patients with colorectal cancer (CRC) will progress and/or develop metastases. Biomarkers capable of predicting progression, risk stratification and therapeutic benefit are needed. Cancer stem cells are thought to be responsible for tumor initiation, dissemination and treatment failure. Therefore, we hypothesized that CRC cancer stem cell markers (CRCSC) will identify a group of patients at high risk for progression.

METHODS: Paraffin-embedded tissue cores of normal (n=8), and histopathologically well-defined primary (n= 30) and metastatic (n=10) CRC were arrayed in duplicate on tissue microarrays (TMAs). Expression profiles of non-CD133 CRCSC (CD29, CD44, ALDH1A1, ALDH1B1, EpCam, and CD166) were detected by immunohistochemistry and the association with clinicopathological data and patient outcomes was determined using standard statistical methodology. An independent pathologist, blinded to the clinical data scored the samples. Scoring included percent positive cells (0 to 4, 0 = <10%, 1 = 10 - 24%, 2 = 25 - 49%, 3 = 50 - 74%, 4 = 75 - 100%), and the intensity of positively stained cells (0 to 4; 0 = no staining, 1 = diminutive intensity, 2 = low intensity, 3 = intermediate intensity, 4 = high intensity). The pathologic score represents the sum of these two values, reported in this paper as a combined IHC staining score (CSS).

RESULTS: Of 30 patients 7 were AJCC stage IIA, 10 stage IIIB, 7 stage IIIC and 6 stage IV. Median follow-up was 113 months. DFI was 17 months. Median overall survival (OS) was not reached. Stage-specific OS was: II - not reached; III - not reached; IV - 11 months. In a univariate analysis, poor OS was associated with loss of CD29 expression; median OS, 32 months vs. not reached for CSS 3-7 vs. >7.5, respectively; p=0.052 comparing entire curves, after adjustment. In a Cox model analysis, loss of CD29 exhibited a trend toward association with survival (p=0.098) after adjusting for the effect of stage (p=0.0076). Greater expression of ALDH1A1 was associated with increasing stage (p=0.042 over stages 2, 3b, 3c, and 4) while loss of CD29 expression exhibited a trend toward being associated with stages 3 and 4 (p=0.08). Compared to normal colon tissue, primary tumors were associated with increased expression of ALDH1B1 (p=0.008). ALD1H1B1 expression level differed according to whether the tumor was moderately or poorly differentiated, well differentiated, or mucinous; the highest expression levels were associated with moderately or poorly differentiated tumors (p=0.011). Lymph node metastases were associated with a trend toward decreased expression of EpCAM (p = 0.06) when comparing 0 vs. 1 vs. 2+ positive lymph nodes, as was CD29 (p = 0.08) when comparing 0 vs. any positive lymph nodes. Compared to normal colon tissue metastatic colon cancers from different patients were associated with increased ALDH1B1 expression (p=0.001) whereas CD29 expression was higher in normal colonic tissue (p=0.014).

CONCLUSION: CD29 may be associated with survival as well as clinical stage and number of lymph nodes. ALDH1B1 expression was associated with differentiation as well as type of tissue evaluated. ALDH1A1 was associated with clinical stage, and decreased EpCAM expression was found in patients with advanced lymph node stage. CRCSCs may be useful biomarkers to risk stratify, and estimate outcomes in CRC. Larger prospective studies are required to validate the current findings.

Keywords: biomarkers; cancer recurrence; cancer stem cells.; colon cancer; lymph node; overall survival; prognosis; staging

References

  1. Arch Surg. 2006 Jun;141(6):527-33; discussion 533-4 - PubMed
  2. Cancer Res. 1998 Mar 15;58(6):1149-58 - PubMed
  3. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 - PubMed
  4. Stem Cells. 2012 Mar;30(3):363-71 - PubMed
  5. World J Gastroenterol. 2009 May 14;15(18):2258-64 - PubMed
  6. N Engl J Med. 2003 Jul 17;349(3):247-57 - PubMed
  7. N Engl J Med. 2000 Jan 13;342(2):69-77 - PubMed
  8. Oncotarget. 2010 Oct;1(6):387-95 - PubMed
  9. Arch Surg. 2012 Jan;147(1):18-24 - PubMed
  10. CA Cancer J Clin. 2007 May-Jun;57(3):168-85 - PubMed
  11. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36 - PubMed
  12. J Clin Oncol. 2007 May 1;25(13):1670-6 - PubMed
  13. N Engl J Med. 2008 Oct 23;359(17):1757-65 - PubMed
  14. Mini Rev Med Chem. 2010 May;10(5):359-71 - PubMed
  15. Semin Liver Dis. 2010 Feb;30(1):26-34 - PubMed
  16. Oncologist. 2010;15(4):390-404 - PubMed
  17. J Anat. 2008 Jul;213(1):59-65 - PubMed
  18. Biochem Biophys Res Commun. 2009 Jan 16;378(3):344-7 - PubMed
  19. Curr Opin Oncol. 2009 Jul;21(4):369-73 - PubMed
  20. Histopathology. 2009 Nov;55(5):564-75 - PubMed
  21. Nature. 2007 Jan 4;445(7123):111-5 - PubMed
  22. Lancet. 1994 Nov 26;344(8935):1470-2 - PubMed
  23. Clin Cancer Res. 2005 Sep 15;11(18):6574-81 - PubMed
  24. Stem Cells Dev. 2011 Oct;20(10):1649-58 - PubMed
  25. J Clin Pathol. 2004 Nov;57(11):1160-4 - PubMed
  26. Br J Surg. 2006 Sep;93(9):1115-22 - PubMed
  27. Nat Rev Cancer. 2008 Oct;8(10):755-68 - PubMed
  28. Br J Cancer. 2010 Jul 27;103(3):382-90 - PubMed
  29. Am J Clin Pathol. 2008 Mar;129(3):424-9 - PubMed
  30. Lancet. 2000 Dec 9;356(9246):1981-2 - PubMed
  31. PLoS One. 2010 Apr 21;5(4):e10277 - PubMed
  32. Int J Colorectal Dis. 2011 Jan;26(1):1-11 - PubMed
  33. Stem Cells. 2012 Apr;30(4):591-8 - PubMed
  34. Cancer Treat Rev. 2012 Feb;38(1):68-75 - PubMed
  35. Nature. 2007 Jan 4;445(7123):106-10 - PubMed
  36. World J Gastroenterol. 2011 Mar 14;17(10):1276-85 - PubMed
  37. Hum Pathol. 1998 Jun;29(6):627-35 - PubMed
  38. Pathol Res Pract. 2005;201(7):479-86 - PubMed
  39. Stem Cells. 2007 Nov;25(11):2903-9 - PubMed
  40. Scand J Gastroenterol. 1998 Jan;33(1):82-7 - PubMed
  41. Ann Surg Oncol. 2012 Feb;19(2):402-8 - PubMed
  42. Mod Pathol. 2007 Feb;20(2):221-32 - PubMed

Publication Types